Liver & Organ Effects

Liver fat reduction, liver-disease questions, cardiovascular-risk populations, and kidney function

Organs Beyond Fat

Retatrutide's glucagon component and phase 2 MRI-PDFF data make it one of the most closely watched investigational agents for liver fat reduction. This unit covers the liver-fat signal, the current limits of the public MASH program, cardiovascular-risk populations in phase 3, and emerging signals in kidney function.

Visualize Liver Fat Reduction

See how retatrutide's glucagon agonism drives liver fat clearance across dose tiers, measured by MRI-PDFF imaging data.

interactive liver fat visualization

Knowledge Check

Test what you've learned about retatrutide's organ-level effects.

Practice Exercises

Reinforce your understanding.